UBS Maintains PROCEPT BioRobotics at Neutral, Raises Price Target to $21
UBS has updated its analyst coverage on PROCEPT BioRobotics, maintaining a 'Neutral' rating and raising the price target to $21 from $20.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS has updated its analyst coverage on PROCEPT BioRobotics, maintaining a 'Neutral' rating and raising the price target to $21 from $20.
Leerink Partners maintained its 'Market Perform' rating on PROCEPT BioRobotics while raising its price target from $20 to $22.
PROCEPT BioRobotics Corporation announced its unaudited financial results for the third quarter ended September 30, 2026.
Grabar Law Office has launched multiple shareholder investigations into four public companies for alleged securities fraud and breach of fiduciary duties. Erasca is accused of making misleading statements about its ERAS-0015 drug candidate and failing to disclose patent infringement risks from Revolution Medicines. Planet Fitness faces allegations of false marketing claims and concealing declining customer acquisition metrics. PROCEPT BioRobotics is investigated for undisclosed discount programs that artificially inflated sales figures and created excess inventory. The Simply Good Foods Company is accused of failing to disclose operational failures and margin erosion related to its OWYN acquisition.